within Pharmacolibrary.Drugs.ATC.J;

model J05AX23
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.36 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 2000 / 1000000,
    adminCount     = 1,
    Vd             = 0.0053,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Ibalizumab is a humanized IgG4 monoclonal antibody used as an antiretroviral for the treatment of multidrug-resistant HIV-1 infection in adults. It acts as a post-attachment inhibitor by binding to domain 2 of the CD4 receptor on T-cells, thereby preventing HIV from entering cells. It was approved by the FDA in 2018 and is currently used in clinical practice for patients with limited treatment options due to resistance.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters were evaluated in HIV-1-infected adults, both male and female, receiving standard dosing of ibalizumab intravenous infusion (initial 2000 mg loading dose followed by 800 mg every two weeks).</p><h4>References</h4><ol><li><p>Beran, C, et al., &amp; Sahloff, EG (2024). A Narrative Review of Novel Agents for Managing Heavily Treatment-Experienced People Living With HIV. <i>The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians</i> 40(4) 194–201. DOI:<a href=&quot;https://doi.org/10.1177/87551225241259894&quot;>10.1177/87551225241259894</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/39157636/&quot;>https://pubmed.ncbi.nlm.nih.gov/39157636</a></p></li><li><p>Jacobson, JM, et al., &amp; Lewis, ST (2009). Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults. <i>Antimicrobial agents and chemotherapy</i> 53(2) 450–457. DOI:<a href=&quot;https://doi.org/10.1128/AAC.00942-08&quot;>10.1128/AAC.00942-08</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/19015347/&quot;>https://pubmed.ncbi.nlm.nih.gov/19015347</a></p></li><li><p>Xu, F, et al., &amp; Wang, K (2017). Current Status of the Pharmacokinetics and Pharmacodynamics of HIV-1 Entry Inhibitors and HIV Therapy. <i>Current drug metabolism</i> 18(8) 769–781. DOI:<a href=&quot;https://doi.org/10.2174/1389200218666170724112412&quot;>10.2174/1389200218666170724112412</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/28738768/&quot;>https://pubmed.ncbi.nlm.nih.gov/28738768</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end J05AX23;
